毛细支气管炎是2岁以下婴幼儿特有的呼吸道感染性疾病,我国国内称之为喘息性肺炎,50%由呼吸道合胞病毒感染,其它副流感病毒、腺病毒、肺炎支原体、鼻病毒亦可感染发病,我国北方多见于冬季和初春,而广东、广西以夏秋季多发。临床以发热、咳嗽、喘憋、呼吸急促为主要表现,重者三凹征阳性,发展为呼吸衰竭、心力衰竭而死亡[1]。笔者在世界卫生组织大力提倡的第三条给药途径(经皮给药)的引导下,采用微波联合阿米迪经皮给药佐治小儿毛细支气管炎,取得了较好的治疗效果,现报道如下。 Bronchiolitis is a specific respiratory infection in infants and young children under 2 years of age. In our country, it is called asthmatic pneumonia and 50% is caused by respiratory syncytial virus. Other parainfluenza virus, adenovirus, Mycoplasma pneumoniae and rhinovirus can also be infected Morbidity, more common in northern China in winter and early spring, Guangdong, Guangxi in summer and fall more. Clinical fever, cough, wheezing, shortness of breath as the main performance, severe positive triple recess, the development of respiratory failure, heart failure and death [1]. Under the guidance of the third route of administration (transdermal administration) advocated by the World Health Organization, the author combined microwave and Amidi’s percutaneous administration to treat children’s bronchiolitis and achieved good therapeutic effect. It is reported as follows.